A novel GHK-based peptidomimetic inhibitor, P6, prevents amyloid beta aggregation and toxicity in Alzheimer's disease models.

The accumulation of amyloid beta (Aβ) peptides is a primary pathological hallmark of Alzheimer's disease (AD). These peptides misfold and aggregate into various toxic forms, including polymorphic oligomers and mature fibrils, which cause widespread neuronal damage. The situation is compounded by the presence of redox-active metal ions, particularly copper (Cu2+), which bind to Aβ and catalyze the production of highly damaging reactive oxygen species (ROS). This multifaceted toxicity—stemming from both protein aggregation and metal-induced oxidative stress—presents a complex therapeutic challenge. Current strategies often target only one aspect of the pathology. This research explores a multifunctional inhibitor designed to simultaneously block Aβ aggregation and chelate copper, addressing both core drivers of neuronal death in AD.

Researchers designed and synthesized a peptidomimetic inhibitor, P6, based on the naturally occurring metal-chelating tripeptide GHK. They used a series of biophysical studies to investigate the interaction between P6 and amyloid beta (Aβ). The study evaluated P6's ability to inhibit the formation of toxic Aβ oligomers and fibrillar aggregates. Its capacity to sequester Cu(2+) from the Aβ-Cu(2+) complex was assessed, along with its effect on subsequent ROS generation. The protective effects of P6 were tested in vitro by observing its ability to prevent Aβ-induced membrane disruption and DNA damage. Finally, the therapeutic potential was validated in a cell model using PC12 cells, which were treated with P6 to measure its efficacy in rescuing cells from multifaceted Aβ toxicity and reducing intracellular ROS levels.

The GHK-based inhibitor P6 demonstrated significant multifunctional activity against amyloid beta (Aβ) toxicity. Biophysical analyses confirmed that P6 directly interacts with Aβ, effectively preventing the formation of both toxic oligomeric species and mature fibrillar aggregates. Furthermore, P6 successfully sequestered copper ions (Cu2+) from the pre-formed Aβ-Cu(2+) complex. By binding the copper, it maintained the metal in a redox-dormant state, which crucially prevented the generation of harmful reactive oxygen species (ROS).

In cellular models, P6 rescued PC12 cells from multifaceted Aβ toxicity. It not only inhibited membrane disruption caused by Aβ oligomers but also efficiently prevented DNA damage induced by the Aβ-Cu(2+) complex. Treatment with P6 significantly reduced the amount of ROS generated within the cells, confirming its protective mechanism extended to a live cellular environment. These results collectively show that P6 can ameliorate the multiple toxic pathways associated with Aβ in Alzheimer's disease.